Lv1
50 积分 2025-03-18 加入
Subcutaneous drug delivery from nanoscale systems
25天前
已完结
Erythrocyte–anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial
1个月前
已完结
In vivo generation of CAR myeloid cells through erythrocyte-mediated mRNA delivery for cancer immunotherapy
1个月前
已完结
In vivo CAR T cell engineering: design principles and open questions
2个月前
已完结
CAR-neutrophils produced in vivo to treat glioma
2个月前
已完结
In vivo CAR T cell generation using retargeted and functionalized lentiviral vectors with reduced immunogenicity
3个月前
已完结
In Vivo Generation of Functional CD19 CAR-T Cells Using a Serum-Stable CD3-Targeted Lentiviral Vector
3个月前
已完结
Intravenous infusion of engineered megakaryocytes to produce oncolytic platelets in vivo for enhanced cancer immunotherapy
3个月前
已完结
Antigen experience history directs distinct functional states of CD8+ CAR T cells during the antileukemia response
4个月前
已完结
Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors
4个月前
已完结
皖公网安备34019202002308
